Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guided Therapeutics Inc (OP: GTHP )

0.1120 UNCHANGED
Streaming Delayed Price Updated: 2:41 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 0.1120
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1120
Today's Range 0.1120 - 0.1120
52wk Range 0.0640 - 0.2499
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
From Guided Therapeutics, Inc.
Via Business Wire
Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
From Guided Therapeutics, Inc.
Via Business Wire

Performance

YTD
-22.87%
-22.87%
1 Month
-6.67%
-6.67%
3 Month
+24.44%
+24.44%
6 Month
-30.00%
-30.00%
1 Year
-55.11%
-55.11%

More News

Read More
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Closes $3.3 Million Bridge Financing
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
From Guided Therapeutics, Inc.
Via Business Wire
New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
From Guided Therapeutics, Inc.
Via Business Wire
Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution
From Guided Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.